IGM Biosciences Inc. News: Why IGMS Stock Is Zooming Higher Today

IGM Biosciences Inc. [IGMS] has traded in a range of $20.34 to $89.81 in the last 1 year. As of this writing, the stock is at $72.60, up 16.05%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, IGMS shares are -7.57% down with the monthly amount drift of 26.38% and seems well in a long time frame.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 5, December 2020, IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting. According to news published on Yahoo Finance, – 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses -.

Analyst Birdseye View:

The most recent analyst activity for IGM Biosciences Inc. [NASDAQ:IGMS] stock was on July 01, 2020, when it was Initiated with a Buy rating from H.C. Wainwright, which also raised its 12-month price target on the stock to $88. Before that, on July 17, 2020, Robert W. Baird Recapitulated an Outperform rating and elevated its amount target to $90. On May 28, 2020, SunTrust Initiated a Buy rating and boosted its price target on this stock to $86. On April 22, 2020, Wedbush Initiated an Outperform rating and increased its price target to $73. On October 14, 2019, Stifel Initiated a Buy rating and increased its price target to $32. On October 14, 2019, Piper Jaffray Initiated an Overweight rating and boosted its amount on this stock to $26. On October 14, 2019, Jefferies Initiated a Buy rating and boosted its target amount on this stock to $25. On the same date Guggenheim Initiated a Buy rating and elevated its amount target to $30.

In the past 52 weeks of trading, this stock has oscillated between a low of $20.34 and a peak of $89.81. Right now, according to Wall Street analyst the average 12-month amount target is $83.78. At the most recent market close, shares of IGM Biosciences Inc. [NASDAQ:IGMS] were valued at $72.60. According to the average price forecast, investors can expect a potential return of 4.27%.


The Principal structure of this organization shows its whole liability to whole principal at 5.78 and the whole liability to whole assets at 5.63. It shows enduring liability to the whole principal at 4.80 and enduring liability to assets at 0.05 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 60.03 points at 1st support level, the second support level is making up to 57.50. But as of 1st resistance point, this stock is sitting at 64.05 and at 65.54 for 2nd resistance point.

IGM Biosciences Inc. [IGMS] reported its earnings at -$0.66 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.69/share signifying the difference of 0.03 and 4.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.62 calling estimates for -$0.64/share with the difference of 0.02 depicting the surprise of 3.10%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for IGM Biosciences Inc. [NASDAQ:IGMS] is 13.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 25.31. Now if looking for a valuation of this stock’s amount to book ratio is 4.84.

Insider Stories

The most recent insider trade was by Chen Daniel ShinYu, Chief Medical Officer, and it was the sale of 608.0 shares on Dec 02. Chen Daniel ShinYu, the Chief Medical Officer, completed a sale of 605.0 shares on Nov 04. On Oct 02, Chen Daniel ShinYu, Chief Medical Officer, completed a sale of 1830.0 shares.